Pneumococcal polysaccharide vaccine 23-valent - Walvax Biotechnology

Drug Profile

Pneumococcal polysaccharide vaccine 23-valent - Walvax Biotechnology

Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Walvax Biotechnology; 23-valent pneumococcal vaccine - Walvax Biotechnology; Pneumococcal 23-valent polysaccharide vaccine - Walvax Biotechnology; PPV-23 - Walvax Biotechnology

Latest Information Update: 26 Nov 2014

Price : $50

At a glance

  • Originator Walvax Biotechnology
  • Developer Fourth Military Medical University; Guangxi Center for Disease Control and Prevention; Walvax Biotechnology
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 01 May 2013 Walvax Biotechnology completes a phase III trial in Pneumococcal infections (In volunteers, Prevention, In adolescents, In adults, In children, In the elderly) in China (IM) (NCT02285036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top